Erasca (ERAS) Stock Recommended for Purchase by JPMorgan
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowErasca, Inc. (ERAS) received an Overweight rating from JPMorgan, which recommends buying the stock at current levels due to anticipated catalysts. H.C. Wainwright also maintains a Buy rating with a price target of $20, following preliminary Phase 1 data for ERAS-0015, which shows potential efficacy in treating non-small cell lung cancer. The data indicates a clear increase in early efficacy, though the safety profile is noted to have some caveats. As a clinical-stage precision oncology company, Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About JPMorgan Chase & Co. (JPM)
JPMorgan Chase is the largest U.S. bank by assets, spanning consumer banking, investment banking, asset management, and payments.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier JPM news
- JPMorgan (JPM) Sexual Assault Suit Impacts Wall Street Attention
- JPMorgan (JPM), Citi (C) Facing Lawsuit Over Payments Dispute
- Anthropic (ANTH) CEO issues warning on software vulnerabilities
- Amazon (AMZN) Price Target Raised to $330 by JPMorgan on AWS Growth
- KLA (KLAC) Stock Price Target Cut by JPMorgan: Valuation Adjusted
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Alphabet (GOOGL) Shares Fall After Q2 Earnings Report
Oct 19
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
JPMorgan (JPM) Cuts Q3 Share Buybacks Amid Growth Focus
Oct 19